Global Blood Therapeutics (GBT) is a publicly-traded, clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing novel therapeutics to improve the lives of patients with grievous blood-based disorders. GBT440, our lead drug candidate, is an oral, once-daily therapy for patients with sickle cell disease (SCD). GBT440 targets the underlying mechanism of red blood cell sickling, which we believe provides the potential to treat SCD rather than only its symptoms. 

We are currently investigating GBT440 in an ongoing Phase 1/2 clinical trials in both healthy subjects and SCD patients. Additionally, we plan to develop GBT440 as a potential therapy for acute and chronic hypoxemic lung disorders, including idiopathic pulmonary fibrosis (IPF) and acute respiratory distress syndrome (ARDS). We are also working to advance an oral kallikrein inhibitor for the prevention of hereditary angioedema (HAE) attacks.